Endeavour Vision

Endeavour Vision is a Geneva-based venture firm that invests in commercially ready, transformative medical technologies that drastically improve clinical outcomes and streamline care delivery. The firm focuses on medical devices, diagnostics, and digital health companies with cleared products, early revenue, or imminent commercial inflection points, where capital can accelerate adoption rather than fund early scientific risk. This commercial-stage discipline distinguishes Endeavour from earlier-stage European medtech investors.

Endeavour writes growth checks of $5M to $25M at Series B, Series C, and Growth stages, often leading or co-leading rounds and taking active board involvement. Geographic scope is transatlantic, spanning Europe and the United States, with portfolio construction explicitly designed to support cross-border commercial scaling.

Founders should approach with regulatory clearances or clear near-term clearance milestones, demonstrated commercial traction, and a credible commercial scaling plan. Expect rigorous diligence on reimbursement strategy, sales productivity, and unit economics. The firm’s value-add concentrates on commercial scale-up and US market entry, so come prepared to discuss how their network and operating perspective accelerate those specific motions.